Hamilton, Ontario (January 29, 2007) -- McMaster scientists are very close to defining small molecule drugs that should be able to redirect the huntingtin protein from accumulating in the wrong place within brain cells, which could potentially translate to a therapy for Huntington's Disease (HD).

There is currently no way to stop or reverse the progression of Huntingtons Disease, which affects one in 10,000 Americans. It is a progressive, and eventually fatal, genetic neurological disease.

Associate professor Ray Truants lab has discovered molecular zip codes or protein sequences in the huntingtin protein that dictate where it goes to within a brain cell.

"We have shown that the mutant huntingtin protein is mis-localized in brain cells in Huntingtons Disease, because it is being improperly signaled, or instructed where to go in the cell," said Truant, of the Department of Biochemistry and Biomedical Sciences.

"In particular, Huntingtin is accumulating at the heart of the cell, the nucleus, where it shouldn't be. This is causing the brain cells to not function properly, and eventually die."

Truant and his university colleagues have received a $260,000 research operating grant from the American-based High Q Foundation. The grant will fund research using the technology of McMasters new Biophotonics Facility and the use of laser microscopy in living brain cells.

It will also use the McMaster High Throughput Screening Facility to screen for new drugs that can affect how huntingtin is signalled.

"This class of small molecule drugs we are now working with has been proven recently to be a very successful class of drugs for different diseases, but not yet in HD," said Truant.

This new type of research is called Chemical Biology and is the focus of a new graduate degree program at McMaster University. The federal Canada Foundation for Innovation recently announced a $8 million grant towa
'"/>

Contact: Veronica McGuire
vmcguir@mcmaster.ca
905-525-9140 x22169
McMaster University
29-Jan-2007